Johnson & Johnson has announced the opening of JLABS @ NYC, a new 30,000-sq. ft. facility located in the New York Genome Center in New York City’s SoHo neighborhood.
A collaboration between Johnson & Johnson Innovation, New York State and the New York Genome Center, JLABS @ NYC can accommodate 30 biotech, pharmaceutical, medical device, and consumer and health tech companies; it is opening with 26 companies, including EpigenCare and Repairogen Corp.
These include the four winners of the JLABS @ NYC QuickFire Challenge, who each received one year of residence at the facility: Lab11 Therapeutics LLC; Manhattan Biosolutions; Sapience Therapeutics, Inc.; and Mobile Sense Technologies, Inc.
JLABS @ NYC is the latest JLAB facility—other locations include San Diego; San Francisco; South San Francisco; Boston; Lowell, Mass.; Houston; Toronto; Beerse, Belgium; and Shanghai.
“For too long, patients and consumers have not fully benefited from the incredible genius throughout the world. NYC and its environs are home to some of the greatest minds in scientific innovation, whose skills and their spirit have so much to offer,” said Melinda Richter, global head of JLABS at Johnson & Johnson Innovation.
"JLABS provides those innovators the environment they need to deliver life-enhancing, life-saving solutions to the people who need them. By opening up vital industry connections, entrepreneurial programs and a capital-efficient, flexible platform to help alleviate the cost burden that typically slows or kills innovation, we know NYC will light up our world.”